The advantages of re-profiling
Re-profiling is the process of taking an existing compound that has been developed for a particular disease indication, and repurposing it for another disease.
The advantages of re-profiling are many, all based around the principle that there is existing knowledge about the candidate compounds. The degree of knowledge varies, depending on whether the re-profiling candidate is in active use in a patient population for an alternative indication, or has only been partially or completely through a development cycle or clinical trial.
Key advantages of re-profiling:
- Compounds with known activity are likely to be active against other targets
- Known toxicology, ADME profiles and side effects
- Safety information is available, particularly for older marketed drugs, which gives lower risk of development failure in Phase II and beyond
- Much development and clinical work has often been done, saving time and money
- Regulatory compliance can be easier to achieve on compounds already used in a patient population.
Re-Pharm builds on these advantages to establish rapid development paths for compounds that we assess to be suitable for re-profiling.